FRI0439 Effects of Different Anti TNF Alpha Treatments on Lipid and Carbohydrate Metabolism in Patients with Rheumatoid Arthritis and Psoriatic Arthritis

BackgroundTNFa plays a key role in the pathogenesis of both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Recent data support the hypothesis that TNFa is involved in the regulation of carbohydrate and lipid metabolism and it is well know that patients with RA and PsA present a high preval...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.594-595
Hauptverfasser: Colia, R., Corrado, A., Maruotti, N., Carriero, A., d'Onofrio, F., Cantatore, F.P.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundTNFa plays a key role in the pathogenesis of both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Recent data support the hypothesis that TNFa is involved in the regulation of carbohydrate and lipid metabolism and it is well know that patients with RA and PsA present a high prevalence of metabolic syndrome and insulin resistance.ObjectivesThe aim of this study is to evaluate the effects of three different anti TNFa drugs on lipid profile, insulin resistance and circulating levels of various adipokines in a cohort of patients with RA and PsA and the possible relationship with activity diseaseMethodsWe evaluated 25 consecutive patients fulfilling the 2010 revised American College of Rheumatology criteria for RA and 66 consecutive patients age and sex matched fulfilling the CASPAR criteria for PsA. At time of recruitment all patients were treated with methotrexate (10 – 15 mg/weekly) and low dose of prednisone (up to 7,5 mg/day). PsA and RA patients were randomly assigned to receive adalimumab (ADA), infliximab (IFX) or etanercept (ETN). For each group we evaluated the effect of treatment on body mass index (BMI), lipid profile, atherogenic index, insulin resistance index (HOMA2-IR), insulin sensitivity index (QUICKI), circulating levels of adipokines (resistin, leptin, adiponectin) and Framingham cardiovascular risk score at baseline (T0) and after 3 (T1) and 6 (T2) months and we correlated these data with disease activity (DAS28).ResultsAt baseline we found that compared to PsA, RA patients presented a significantly higher disease activity (p
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2016-eular.4675